Refractory epilepsy as a structural consequence of Pallister-Killian syndrome: a case report
Abstract
Case Presentation: A 3-year-old male patient whose gestational period was marked by increased nuchal translucency (10.3 mm), suggesting a possible chromosomal abnormality. He was delivered at 37 weeks via cesarean section, with Apgar scores of 5 and 8, requiring neonatal resuscitation. At birth, multiple congenital malformations were identified, including agenesis of the corpus callosum, polymicrogyria, optic nerve hypoplasia, and renal malformation. Given the syndromic phenotype, genetic investigation confirmed Pallister-Killian Syndrome (PKS), characterized by tetrasomy of the short arm of chromosome 12 (47,XY,+i(12)(p10)), identified through fibroblast karyotyping due to typical tissue mosaicism. The patient currently presents with profound psychomotor delay and requires intensive support. The neurological condition is marked by refractory epilepsy, which began at 7 months of age with ocular deviation and limb extension, progressing to frequent tonic seizures associated with intense postictal crying. Multiple antiseizure medications were used, including phenobarbital, levetiracetam, clobazam, oxcarbazepine, and valproate, with limited efficacy and no sustained seizure control. Discussion: Pallister-Killian Syndrome is a rare sporadic disorder caused by the presence of an extra isochromosome of the short arm of chromosome 12, resulting in tissue mosaicism. Abnormal cells are often underrepresented in peripheral blood but more prevalent in skin and buccal mucosa, making fibroblast karyotyping the diagnostic gold standard. The pathophysiology involves gene overdosage in the 12p region, including genes such as CCND2, which is involved in cell proliferation and neuronal migration. This imbalance leads to severe central nervous system malformations, including polymicrogyria and corpus callosum dysgenesis, both observed in this case. These structural abnormalities result in disorganized cortical architecture, creating persistent epileptogenic foci. This explains the high prevalence and pharmacoresistance of epilepsy in PKS, as seizures arise from structural neuronal abnormalities rather than purely neurochemical dysfunction. In this patient, video-electroencephalography demonstrated diffuse low-amplitude beta ictal activity during clinical events, supporting widespread cortical instability. Final Comments: Epilepsy in PKS should be understood as a direct consequence of cortical malformations driven by genetic imbalance. The presence of characteristic dysmorphisms and neuroimaging findings should prompt targeted investigation in non-blood tissues to avoid false-negative results. Although seizure control remains challenging, stabilization is essential to allow even modest cognitive and motor improvements, which are crucial for quality of life and reduction of systemic complications.